Page 421 - شرور شركات الأدوية

‫ﻣﻼﺣﻈﺎت‬

(19) Safer DJ. Design and reporting modifications in industry-
sponsored comparative psychopharmacology trials. J. Nerv. Ment. Dis.
2002 Sep;190(9):583–92.

(20) Gilbody S, Wahlbeck K, Adams C. Randomized controlled trials in
schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand.
2002;105:243–251.

(21) Montori VM, Jaeschke R, Schünemann HJ, Bhandari M, Brozek JL,
Devereaux PJ, et al. Users’ guide to detecting misleading claims in clinical
research reports. BMJ. 2004 Nov 6;329(7474):1093–6.

(22) Shaughnessy AF, Slawson DC. What happened to the valid POEMs?
A survey of review articles on the treatment of type 2 diabetes. BMJ. 2003
Aug 2;327(7409):266.

(23) Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence
b(i)ased medicine—selective reporting from studies sponsored by phar-
maceutical industry: review of studies in new drug applications. BMJ
2003;326:1171–3.

(24) Vedula, S Swaroop, Lisa Bero, Roberta W Scherer, and Kay Dick-
ersin. ‘Outcome reporting in industry-sponsored trials of gabapentin for
off-label use.’ The New England Journal of Medicine 361, no. 20 (November
12, 2009): 1963–1971.

(25) Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG:
Empirical evidence for selective reporting of outcomes in randomized tri-
als: comparison of protocols to published articles. JAMA 2004, 291:2457–
2465.

(26) Jon N. Jureidini, Leemon B. McHenry, Peter R. Mansfield. Clinical
trials and drug promotion: Selective reporting of study 329. International
Journal of Risk & Safety in Medicine 20 (2008) 73–81 73 DOI 10.3233/JRS-
2008-0426.

421